Senti Biosciences (NASDAQ:SNTI) Shares Up 1.6% – Should You Buy?

Shares of Senti Biosciences, Inc. (NASDAQ:SNTI) shot up 1.6% during mid-day trading on Wednesday . The stock traded as high as $0.95 and last traded at $0.9450. 117,479 shares traded hands during mid-day trading, a decline of 37% from the average session volume of 187,042 shares. The stock had previously closed at $0.93.

Analysts Set New Price Targets

SNTI has been the topic of several recent research reports. Chardan Capital raised their target price on Senti Biosciences from $12.00 to $13.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Wall Street Zen raised Senti Biosciences to a “sell” rating in a research note on Saturday, December 13th. Leerink Partners began coverage on Senti Biosciences in a report on Friday, November 21st. They issued an “outperform” rating and a $6.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Senti Biosciences in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Senti Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $9.00.

Senti Biosciences Trading Up 1.6%

The stock has a fifty day simple moving average of $1.02 and a 200-day simple moving average of $1.47. The stock has a market cap of $24.84 million, a price-to-earnings ratio of -0.28 and a beta of 2.13.

Institutional Trading of Senti Biosciences

Hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new position in shares of Senti Biosciences during the fourth quarter valued at about $40,000. Virtu Financial LLC bought a new position in Senti Biosciences during the fourth quarter valued at about $46,000. Citadel Advisors LLC acquired a new position in Senti Biosciences in the 3rd quarter valued at approximately $117,000. Geode Capital Management LLC raised its holdings in Senti Biosciences by 395.6% in the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after acquiring an additional 117,588 shares in the last quarter. Finally, Armistice Capital LLC bought a new stake in shares of Senti Biosciences in the 2nd quarter worth approximately $1,883,000. 25.70% of the stock is owned by institutional investors.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.